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ABSTRACT 
Bacille Calmette-Guerin (BCG) vaccine, developed by Calmette and Guerin at Institute Pasteur (Lille, France), is a live-
attenuated Mycobacterium bovis strain. There are many therapeutic uses of the species have been described, Intravesical BCG 
has been established as an effective treatment of superficial bladder cancer. A 66-year old gentleman with newly diagnosed 
superficial high-grade papillary transitional cell carcinoma involving lamina propria (T1) of the bladder underwent 3 cycles of 
intravesical BCG. First 2 cycles were uneventful and tolerated well. After 3rd BCG cycle, patient developed granulomatous 
hepatitis with disseminated Koch's. BCG-induced sepsis after intra-vesical instillation for bladder cancer is a rare complication. 
Pathophysiology remains largely unknown, but BCG’s low virulence suggests that immunological hypersensitivity reaction 
probably plays a role. There have been no prospective studies to evaluate the optimal treatment for BCG infection. 
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ntravesical instillation of bacilli Calmette-Guerin 
(BCG) has been established as an effective modality 
for superficial bladder cancer. Complication of 
intravesical BCG ranges from dysuria to disseminated 
Koch’s. Complications can appear early (within 3 months 
after instillation) or years after first BCG treatment [1]. 
Early presenting disease is characterized by generalized 
symptoms, hepatitis and pneumonitis. Late presenting 
disease is usually localized, with no systemic 
manifestations and the infection involves often the 
genitourinary tract and other sites that are typical for 
reactivation of mycobacterial disease, such as the vertebral 
spine or retroperitoneal tissue [1]. Certain aspects 
concerning its diagnostic and treatment are still debatable 
[2]. We herein report 65 year male developing 
granulomatous hepatitis with disseminated Koch’s 
secondary to Intravesical BCG. 
 
CASE REPORT 
A 66-year-old gentleman with newly diagnosed superficial 
high-grade papillary transitional cell carcinoma involving 
lamina propria (T1) of the bladder underwent 3 cycles of 
intravesical BCG. First 2 cycles were uneventful and 
tolerated well. After 3
rd
 BCG cycle, patient presented with 
fever, and dysuria. Initially, he was treated as grade 1 BCG 
adverse reaction with supportive treatment. After few days 
down the line, patient presented with jaundice, on and off 
fever, joint pain, and malaise. On investigations, liver 
function test was deranged (Total serum bilirubin-
6.5mg/dl, indirect component-3.8, SGPT-650U, SGOT-
540U, Alkaline phosphatase-170IU/L) and had leukopenia 
(WBC-2100) routine aerobic urine culture and blood 
culture did not yield any pathogen. Chest X-ray was 
unremarkable. Ultrasonography of abdomen suggestive of 
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hepatomegaly with altered ecotexture of liver parenchyma. 
Patient underwent Contrast Enhanced CT scan of 
Abdomen and pelvis; suggest hepatomegaly, 
heterogeneous liver parenchyma with gall bladder edema. 
In view of deranged LFT and CT scan findings, CT 
guided liver biopsy was performed which showed 
granulomatous hepatitis with non-caseating granuloma 
(fig. 1) suggestive of tubercular etiology. Worsening 
pancytopenia prompted a bone marrow biopsy that 
revealed multiple large noncaesating granulomas. 
 
Fig 1: liver biopsy showing granulomatous hepatitis With 
multinucleate giant cell epitheloid granuloma 
Liver biopsy tissue and bone marrow biopsy tissue 
also sent for AFB culture and TB PCR. TBPCR was 
negative. AFB cultures were also negative after 8 weeks of 
incubation (BD MGIT 320 TB SYSTEM). In view of 
biopsy report, patient was put on anti-koch’s therapy for 6 
month (Isoniazid 5mg/kg/day; pyrazinamide 50mg/kg/day; 
ethambutol 15mg/kg/day) and short course of 
corticosteroid (prednisolone 20mg twice a day and tapered 
gradually). Patient gradually improved and his fever 
subsided within several day of anti-tuberculosis therapy. 
DISCUSSION 
The intravesical administration of BCG has become 
modality of treatment for superficial bladder cancer [3, 4]. 
Bacille Calmett-Guerin (BCG) is a low virulence 
mycobacteria originated from successive culture of 
mycobacterium bovis [5]. Initially BCG was used to 
vaccinate the cattle to prevent tuberculosis and later used 
in humans [1]. 
Mechanism of action of BCG in bladder cancer is 
largely unknown and probably is specific anti-BCG cell 
mediated immunity, inducing the production of large 
amounts of cytokines that draw cytotoxic activity by 
natural killer cells against transitional cancer cells [6]. The 
pathogenic mechanism underlying the development of 
complications is unclear, but BCG’s low virulence 
suggests that immunological hypersensitivity reaction 
probably plays a role. Complication ranges from lower 
urinary tract symptoms (LUTS) to organ involvement and 
disseminated infection. Localized and late infection can 
involve bone, muscle, vessels (aneurysms and 
pseudoaneurysm), eyes (granulomatous anterior uveitis, 
endophthalmitis, and autoimmune retinopathy) and 
genitourinary tract (cystitis, sterile pyuria, nephritis and 
epididymo-orchitis) [7-9]. Diagnosis of BCG related sepsis 
frequently challenging since symptoms are indistinct from 
the other causes of sepsis like bacteremia, urinary tract 
infections, respiratory infections (pneumonia), viral 
hepatitis, etc. 
Pre-existing cystitis or persistent hematuria following 
transurethral resection of bladder tumor is main 
predisposing factor [8]. Lamm et al. [10] have suggested 
that fever or shivering during or shortly after BCG 
intravesical instillation may be predictive for the risk of 
developing severe infection. Previous tuberculosis or latent 
tuberculosis infections do not seem to be higher risk of 
BCG complications [1]. It is known that diabetic patient 
have greater risk of developing tuberculosis and that poor 
glycemic control is associated with complication from 
intravesical BCG [1]. Quanti FERON-TB Gold test 
positivity only indicates previous contact with 
Mycobacterium tuberculosis and it is not useful for 
diagnosis of BCG complications. Staining of specimens 
for acid-fast bacilli, cultures and PCR testing for 
mycobacterial DNA should be performed in any patient 
with suspected disseminated BCG infection, even though 
all of these procedures can be negative in some cases. 
Concurrent prophylactic use of isoniazid with 
intravesical instillation has largely been unsuccessful. On 
the contrary, prophylactic use of fluroquinolones may be 
more effective [11, 12]. Some authors recommend 
screening with Mantoux test. Active tuberculosis has to be 
ruled out. Use of corticosteroid is convincing in early 
course of therapy. 
CONCLUSION 
Post intravesical BCG complication and adverse reactions 
has wide range of presentation from dysuria to 
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disseminated sepsis. Even initial cycles were well 
tolerated; subsequent dosage can leads to complications. 
Usually the symptomatology is nonspecific, hence need 
high index of suspicion for the diagnosis and to prevent 
further complications. Systemic 3 drug anti-tuberculous 
therapy has well proven role in literature for post BCG 
sepsis. 
REFERENCES 
1. Colomba C, Di Carlo P, Guadagnino G, Siracusa L, 
Trizzino M, Gioè C, et al. A case of epididymo-orchitis 
after intravesical bacilli Calmette-Guérin therapy for 
superficial bladder carcinoma in a patient with latent 
tuberculosis infection. Infect Agent Cancer. 2016; 11: 25. 
2. Figueiredo C, Póvoas D, Alves C, Ferreira A, 
Figueiredo P, Carvalho T, et al. Septic Shock after 
Intravesical BCG Instillation - A Case Report. Advances 
in Infectious Diseases. 2013; 3(4):243-7. 
3. Vazquez-Lavista LG, Flores-Balcazar CH, Llorente L. The 
bacillus Calmette-Guerin as immunomodulator in bladder 
cancer. Rev Invest Clin. 2007; 59(2): 146–52. 
4. Houghton BB, Chalasani V, Hayne D, Grimison P, Brown 
CS, Patel MI, et al. Intravesical chemotherapy plus bacille 
Calmette-Guerin in non-muscle invasive bladder cancer: a 
systematic review with meta-analysis. BJU Int. 2013; 
111(6): 977-83. 
5. Andrade E Silva UV, Viana Lde S, Oliveira E Castro Pde 
T, Almeida RD, Silva RS. Fatal Sepsis after Intravesical 
Instillation of BCG: Case Report. Rev Bras Ter Intensiva. 
2011; 23(1): 104-7. 
6. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, 
James K. Mechanisms of action of intravesical bacille 
Calmette-Guerin: local immune mechanisms. Clin Infect 
Dis. 2000; 31Suppl 3: S91–3. 
7. Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour 
MR, Septimus EJ, et al. Spectrum of bacille Calmette-
Guerin (BCG) infection after intravesical BCG 
immunotherapy. Clin Infect Dis. 2003; 36 (2): 140–8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-
Medrano F, Lumbreras C, Tejido A, San Juan R, et al. 
Bacillus Calmette-Guerin (BCG) infection following 
intravesical BCG administration as adjunctive therapy for 
bladder cancer: incidence, risk factors, and outcome in a 
single-institution series and review of the literature. 
Medicine (Baltimore). 2014; 93(17): 236–54. 
9. Nam EY, Na SH, Kim SY, Yoon D, Kim CJ, Park KU, et 
al. Infected Aortic Aneurysm caused by Mycobacterium 
bovis after Intravesical Bacillus Calmette-Guerin 
Treatment for Bladder Cancer. Infect Chemother. 2015; 
47(4): 256–60. 
10. Lamm DL. Efficacy and Safety of Bacille Calmette-
Guérin Immunotherapy in Superficial Bladder Cancer. 
Clin Infec Dis. 2000; 31 Suppl 3: S86-90. 
11. Van der Meijden AP, Brausi M, Zambon V, Kirkels W, de 
Balincourt C, Sylvester R, et al. Intravesical instillation of 
epirubicin, bacillus Calmette-Guerin and bacillus 
Calmette-Guerin plus isoniazid for intermediate and high 
risk Ta, T1 papillary carcinoma of the bladder: a 
European Organization for Research and Treatment of 
Cancer genito-urinary group randomized phase III trial. J 
Urol. 2001; 166: 476–81. 
12. Colombel M, Saint F, Chopin D, Malvaud B, Nicolas L, 
Rischmann P. The effect of ofloxacin on bacillus 
calmette-guerin induced toxicity in patients with 
superficial bladder cancer: results of a randomized, 
prospective, double blind, placebo controlled, multicenter 
study. J Urol. 2006; 176(3): 935–9. 
How to cite this article: Ghule RR, Shivde SR, Daga 
RN. Intra-vesical BCG induced granulomatous hepatitis 
and disseminated Koch’s: Our experience. Indian J Case 
Reports. 2017; 3(1): 47-49. 
Conflict of interest: None stated, Funding: Nil 
